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Introduction
Prenatal ultrasound is a powerful tool for the detection
of structural abnormalities of fetuses in trisomy 13 preg-
nancies [1]. This article provides a comprehensive review
of the prenatal sonographic features of trisomy 13
fetuses in the second and third trimesters, including cys-
tic hygroma and nuchal edema, congenital heart defects
(CHD), hydrops fetalis, omphalocele, diaphragmatic
hernia, urinary tract abnormalities, and abnormal
extremities and polydactyly.
Cystic Hygroma and Nuchal Edema
Cystic hygroma is characterized by a bilateral septated
cystic structure in the occipitocervical region. About
75% of second-trimester fetuses with cystic hygroma
demonstrate chromosomal abnormalities, with Turner
syndrome accounting for 80% of the cases [2]. Azar 
et al [2] found that 33 of 44 fetuses with cystic hygroma
in the second trimester had chromosomal abnormali-
ties, including Turner syndrome (n = 31), trisomy 18
(n = 1) and trisomy 21 (n = 1). In a meta-analysis of
276 fetuses with prenatally diagnosed cystic hygroma,
Snijders et al [3] reported chromosomal abnormalities
in 68%, including 45,X (n = 163), trisomy 21 (n = 26),
trisomy 18 (n = 13) and other rearrangements (n = 11).
They also reported that cystic hygroma was diagnosed
in 88% of fetuses with Turner syndrome (n = 65), 2% of
fetuses with trisomy 18 (n = 137) and 1% of fetuses
with trisomy 21 (n = 38).
Nuchal edema is characterized by subcutaneous
edema in the midsagittal plane of the neck, producing
a characteristic tremor on ballottement of the fetal
head. About one-third of fetuses with nuchal edema
have chromosomal abnormalities, mainly trisomies
21, 18 and 13 [4]. Nicolaides et al [4] reported chro-
mosomal abnormalities in 36.6% (53/145) of fetuses
with nuchal edema, including trisomy 21 (n = 31), tri-
somy 13 (n = 7), trisomy 18 (n = 5), Turner syndrome
(n = 3), triploidy (n = 2), partial trisomy 4q (n = 1),
tetrasomy 12p (n = 1), 4p deletion (n = 1), 5q deletion
(n = 1) and 14q deletion (n = 1). In a meta-analysis of
371 fetuses with prenatally diagnosed nuchal edema,
Snijders et al [3] reported chromosomal abnormalities
in 33% of the fetuses, including trisomy 21 (n = 85),
trisomy 18 (n = 9), 45,X (n = 10) and other rearrange-
ments (n = 19). They also reported nuchal edema in
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38% of fetuses with trisomy 21 (n = 38), 22% with 
trisomy 13 (n = 54), 5% with trisomy 18 (n = 137), 6%
with Turner syndrome (n = 65), and 4% with triploidy
(n = 50).
Nicolaides et al [5] found nuchal edema in 22.6%
(7/31) of fetuses with trisomy 13. Wladimiroff et al [6]
found cystic hygroma in 11.8% (2/17) of fetuses with
trisomy 13, all of whom were diagnosed before 20
weeks’ gestation. Lehman et al [7] found nuchal thick-
ening/cystic hygroma in 21.2% (7/33) of fetuses with
trisomy 13, six of whom were diagnosed at 12–20 weeks’
gestation, while one was diagnosed at 20–32 weeks’
gestation. De Vigan et al [8] found cystic hygroma in
15.5% (9/58) of fetuses with trisomy 13. Tongsong 
et al [9] found nuchal edema in 6.7% (1/15) of fetuses
with trisomy 13, while Papp et al [10] found nuchal
thickening > 6 mm in 21.4% (6/28) of fetuses with tri-
somy 13. The mean frequency of nuchal edema/cystic
hygroma/nuchal thickening in trisomy 13, based on
the six published series on second- and third-trimester
fetal trisomy 13 fetuses, is 17.6% (32/182).
About 50% of first-trimester fetuses with cystic
hygroma demonstrate chromosome abnormalities, with
autosomal trisomies accounting for 60% of the cases
and Turner syndrome accounting for 30%. Ville et al
[11] reported chromosomal abnormalities in 28.6%
(16/56) of fetuses with first-trimester cystic hygroma,
including trisomy 18 (n = 6), trisomy 21 (n = 5), 45,X
(n = 4) and 47,XXX (n = 1). Johnson et al [12] reported
chromosomal abnormalities in 60.3% (41/68) of
fetuses with first-trimester cystic hygroma, including
trisomy 21 (n = 16), trisomy 18 (n = 9), trisomy 13 (n =
2), 45,X (n = 9), der(10)t(4;10) (n = 1), t(1;18) (n = 1),
mosaic 46,XY/45,X (n = 1), mosaic 46,XY/47,XX, + mar
(n = 1) and der(18)t(7;18) (n = 1). Trauffer et al [13]
reported chromosomal abnormalities in 48.8% (21/
43) of fetuses with first-trimester cystic hygroma,
including trisomy 21 (n = 9), trisomy 18 (n = 4), trisomy
13 (n = 1), Turner syndrome (n = 4) and translocations
(n = 3). Malone et al [14] reported chromosomal
abnormalities in 50.8% (67/132) of fetuses with first-
trimester septated cystic hygroma, including trisomy
21 (n = 25), Turner syndrome (n = 19), trisomy 18 (n =
13), trisomy 13 (n = 6), triploidy (n = 3) and mosaic
deletion of chromosome 9 (n = 1). Kharrat et al [15]
reported chromosomal abnormalities in 59.5% (25/
42) of fetuses with first-trimester cystic hygroma,
including trisomy 18 (n = 10), trisomy 13 (n = 6) and
45,X (n = 9). Graesslin et al [16] reported chromo-
somal abnormalities in 52.8% (38/72) of fetuses with
first-trimester cystic hygroma, including trisomy 21
(n = 14), trisomy 18 (n = 7), trisomy 13 (n = 3), Turner
syndrome (n=11) and other rearrangements (n=3). In a
meta-analysis, Molina et al [17] found chromosomal
abnormalities in 53.1% (139/262) of fetuses with first-
trimester cystic hygroma, including trisomies 21, 18
and 13 (n = 84), Turner syndrome (n = 42), and other
rearrangements (n = 13).
Congenital Heart Defects
CHD have been found in 90% of fetuses with trisomy
13 [18]. The most common CHD in trisomy 13 fetuses
include ventricular septal defects, atrial septal defects,
patent ductus arteriosus, overriding aorta, dextroposi-
tion, hypoplastic aorta, atretic mitral and/or aortic
valves, pulmonary stenosis, and anomalous pulmonary
venous return [19]. The reported frequencies of prena-
tally detected CHD in fetuses with trisomy 13 in the
second and third trimesters has varied, ranging from
29.3% (17/58) [8] to 33.3% (5/15) [9], 45.2% (14/31)
[5], 48.5% (16/33) [7], 50.0% (9/18) [20], 53.6%
(15/28) [10], 57.4% (31/54) [21] and 70.6% (12/17)
[6]. The mean frequency of prenatally detected CHD,
based on the eight published series on trisomy 13, is
47.2% (119/252).
Lehman et al [7] reported that 48.5% (16/33) of
fetuses with trisomy 13 had CHD, including hypoplas-
tic left heart (n = 7) and ventricular septal defects
(n = 6). Picklesimer et al [20] reported cardiovascular
defects in 53% of fetuses with trisomy 13 (n = 18),
including ventricular septal defects (n = 3), atrioven-
tricular canal defects (n = 2) and hypoplastic left heart
(n = 4). Papp et al [10] reported that 53.6% (15/28) of
fetuses with trisomy 13 had CHD, including ventricular
septal defects (n = 4), dilated right chamber (n = 4),
outflow tract abnormalities (n = 2), hypoplastic left
ventricle (n=2), coarctation of the aorta (n=1), truncus
arteriosus communis (n = 1) and tricuspid regurgitation
(n = 1). Papp et al [10] also showed that 9.4% (5/53) of
fetuses with trisomy 13 presented with CHD as the only
sonographic feature. Watson et al [21] reported that
57.4% (31/54) of fetuses with trisomy 13 had CHD,
including an atrial septal defect/ventricular septal defect/
atrioventricular canal (n = 11), multiple anomalies/
complex (n = 10), a single ventricle (n = 6), an axis shift
(n = 3) and tetralogy of Fallot (n = 1).
CHD have been found in 1% of the general popula-
tion [18]. When CHD is identified in early infancy,
there is a 5–10% frequency of chromosomal abnormal-
ities [22,23]. Chromosomal abnormalities that are
commonly associated with CHD include trisomy 21, tri-
somy 18, trisomy 13, tetrasomy 22p (cat-eye syndrome),
tetrasomy 12p (Pallister-Killian syndrome), 45,X (Turner
syndrome), 4p deletion (Wolf-Hirschhorn syndrome),
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7q11.23 deletion (Williams syndrome), 20p12 deletion
(Alagille syndrome), 22q11.2 deletion (DiGeorge syn-
drome), distal 11q deletion, 8p deletion involving
8p22.23, and 3p deletion involving 3p25 [24]. Most
chromosomal abnormalities are associated with an in-
creased incidence of CHD. For instance, CHD have
been found in more than 90% of fetuses with trisomy
18, 90% with trisomy 13, 50% with trisomy 21, 67%
with trisomy 22, 40% with cat-eye syndrome, about
40% with Wolf-Hirschhorn syndrome, about 20% with
cri-du-chat syndrome, about 50% with mosaic trisomy 8,
more than 50% with mosaic trisomy 9, about 25% with
13q deletion, more than 50% with partial trisomy 14q,
less than 50% with 18q deletion, 14% with 49,XXXXY,
and 35% with Turner syndrome [18].
Wladimiroff et al [25] detected CHD by ultrasound
in 13 of 230 fetuses and detected chromosomal abnor-
malities in 38.5% (5/13) of the fetuses with CHD, in-
cluding trisomy 18 (n=3), trisomy 21 (n=1) and trisomy
13 (n=1). Copel et al [26] detected CHD by ultrasound
in 34 of 502 fetuses, and chromosomal abnormalities
in 32.4% (11/34) of the fetuses with CHD, including
trisomy 18 (n=4), trisomy 21 (n=2), trisomy 13 (n=1),
trisomy 9 (n = 1), 47,XXY (n = 1), and 45,X (n = 1).
Paladini et al [27] detected CHD by ultrasound in 31 of
469 fetuses, and chromosomal abnormalities in 48.4%
(15/31) of the fetuses with CHD, including trisomy 21
(n=6), trisomy 18 (n=4), trisomy 13 (n=4) and triploidy
(n = 1). In their study, fetuses with cardiac and extra-
cardiac anomalies carried a higher risk  of aneuploidy
than those with isolated cardiac anomalies (71.4%
[10/14] vs. 29.4% [5/17]), and atrial septal defects
and ventricular septal defects were the cardiac anom-
alies most often associated with aneuploidies (77% vs.
71%, respectively). Brown et al [28] found that 34.4%
(43/125) of fetuses with CHD had chromosomal
abnormalities, including trisomy 18 (n = 16), trisomy
21 (n = 9), trisomy 13 (n = 6), 45,X (n = 4), triploidy
(n = 2) and other rearrangements (n = 6). The karyotype
was abnormal in 63.5% (33/52) of the fetuses with
coexisting noncardiac anomalies, compared with 13.7%
(10/73) of those fetuses without coexisting noncar-
diac anomalies. In a meta-analysis of 829 fetuses with
prenatally detected CHD, Snijders et al [3] reported
chromosomal abnormalities in 29% of the cases, includ-
ing trisomy 21 (n = 68), trisomy 18 (n = 82), trisomy 13
(n = 30), 45,X (n = 30) and other rearrangements
(n = 31). In their study, chromosomal abnormalities
were found in 16% of the cases with apparently iso-
lated heart defects and 65% of those with additional
abnormalities. Snijders et al [3] also reported that
CHD were observed in 52% of fetuses with trisomy 18
(n = 137), 48% with Turner syndrome (n = 5), 43% with
trisomy 13 (n = 54), 26% with trisomy 21 (n = 155), and
16% with triploidy (n = 50). Chaoui et al [29] detected
CHD by ultrasound in 203 of 2,716 fetuses and chro-
mosomal abnormalities in 22.7% (46/203) of the fetuses
with CHD, including trisomy 18 (n = 15), trisomy 21
(n=13), trisomy 13 (n=5), 45,X (n=5), triploidy (n=2)
and other rearrangements (n = 6). In their study, 8/15
of the fetuses with trisomy 18 had a ventricular septal
defect, 9/13 with trisomy 21 had an atrioventricular
septal defect, and 5/5 with 45,X had a left heart out-
flow obstruction, but the fetuses with trisomy 13, tri-
ploidy and other rearrangements did not have typical
cardiac defects. Chaoui et al [29] additionally found
that the aneuploidy incidences for specific CHD were
55% for an atrioventricular septal defect, 43% for a
ventricular septal defect, 43% for aortic coarctation,
36% for tetralogy of Fallot, 36% for double outlet right
ventricle, and none for isomerism, transposition of the
great arteries, pulmonary atresia or stenosis.
Prenatal diagnosis of an atrioventricular septal defect
is associated with a 50% risk of aneuploidy, mainly tri-
somy 21. Delisle et al [30] found that 57.9% (22/38)
of fetuses with an atrioventricular septal defect had chro-
mosomal abnormalities, including trisomy 21 (n = 19),
trisomy 18 (n = 1), trisomy 13 (n = 1) and mosaic tri-
somy 19q (n = 1). Huggon et al [31] found that 49.1%
(107/218) of fetuses with an atrioventricular septal
defect had chromosomal abnormalities, including tri-
somy 21 (n=86), trisomy 18 (n=13), trisomy 13 (n=4),
48,XYY, +21 (n = 1), 8q deletion (n = 1), unbalanced
translocation of 14/21 (n = 1), 22q11 microdeletion
(n = 1) and unknown fragment to 12 (n = 1).
Song et al [32] found chromosomal abnormalities
in 28.1% (94/334) of fetuses with major CHD, includ-
ing trisomy 21 (n = 41), trisomy 18 (n = 18), trisomy 
13 (n = 9), 45,X (n = 7), 22q11.2 deletion (n = 7) and
other rearrangements (n = 10). In their study, chromo-
somal abnormalities were not found in fetuses with
aortopulmonary window (0/1), anomalous pulmonary
venous connection (0/2), ectopia cordis (0/4), hetero-
taxy (0/32), single ventricle (0/12) or transposition of
the great arteries (0/15). In contrast, chromosomal
abnormalities were found in fetuses with: (1) aortic
stenosis (1/9, 11.1%), including trisomy 18 (n = 1); (2)
atrioventricular septal defect (39/53, 73.6%), including
trisomy 21 (n = 34), trisomy 18 (n = 3), 45,X (n = 1) and
3p + (n = 1); (3) coarctation of the aorta/arch interrup-
tion (7/19, 36.8%), including trisomy 21 (n=1), trisomy
18 (n=1), trisomy 13 (n=1) and del(14)(q32.1) (n=1);
(4) double outlet right ventricle (12/28, 42.9%), including
trisomy 18 (n=5), trisomy 13 (n=5), 47,XXY,der(13;14)
(q10;q10) (n = 1) and 47,XX, +der(Y)t(Y;14)(q12;q22)
(n = 1); (5) hypoplastic left heart syndrome (6/66,
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9.1%), including trisomy 13 (n = 1), 45,X (n = 3),
t(1;4)(p13.1;p15.3) (n = 1) and inv(1)(q42.12q42.13)
(n = 1); (6) pulmonary stenosis or atresia with intact
ventricular septum (3/24, 12.5%), including trisomy 21
(n=1), trisomy 18 (n=1) and der(12)t(4;12) (p15;q24)
(n = 1); (7) tricuspid atresia (2/14, 14.3%), including
trisomy 18 (n = 1) and mosaic trisomy 22 (n = 1); (8)
tetralogy of Fallot (13/33, 39.4%), including trisomy 21
(n = 3), trisomy 18 (n = 4), trisomy 13 (n = 1), 22q11.2
deletion (n = 3), 49,XXXXY (n = 1) and mosaic trisomy
14 (n=1); (9) truncus arteriosus (7/9, 77.8%), including
trisomy 18 (n = 1), trisomy 13 (n = 1), 22q11.2 deletion
(n = 3), 92,XXYY (n = 1) and mosaic rec(1),dup(1q) (n =
1); (10) tricuspid valve dysplasia (including Ebstein’s
anomaly) (2/12, 16.7%), including trisomy 21 (n = 2);
and (11) vascular ring (2/2 = 100%), including trisomy
18 (n = 1) and 22q11.2 deletion (n = 1). In the seven
cases with 22q11.2 deletion, Song et al [32] found
that three had truncus arteriosus, three had tetralogy
of Fallot, and one had a vascular ring.
Hydrops Fetalis
Hydrops fetalis occurs in approximately 1 per 1,000
births and may be the consequence of fetal or maternal
disorders such as hematologic, cardiovascular, renal,
pulmonary, gastrointestinal, hepatic, metabolic, chro-
mosomal, neoplastic, infectious, placental or umbilical
cord disorders [3]. In a meta-analysis of 600 fetuses with
nonimmune hydrops fetalis, Jauniaux et al [33] reported
chromosomal abnormalities in 15.7% (94/600) of fe-
tuses, including trisomy 21 (n = 36), Turner syndrome
(n = 33), trisomy 18 (n = 7), triploidy (n = 5), trisomy 13
(n = 3), trisomy 16 (n = 1) and other chromosomal re-
arrangements (mosaicism, translocations, deletion of the
short arm of chromosome 13, and pericentric inversions)
(n = 9). Snijders et al [3] found that hydrops fetalis
was diagnosed in 80% of fetuses with Turner syndrome
(n=65), 20% with trisomy 21 (n=155), 7% with trisomy
13 (n = 54), 4% with trisomy 18 (n = 137), and 2% with
triploidy (n = 50). The reported frequencies of hydrops
fetalis in fetuses with trisomy 13 range from 6.5%
(2/31) [5] to 6.9% (4/58) [8] and 12.1% (4/33) [7].
Omphalocele
Chromosomal abnormalities have been reported in
10–12% of neonates with omphalocele and 30% of fe-
tuses with omphalocele [34–39]. When the diagnosis is
made in early pregnancy, the incidence of aneuploidy
can increase to 61.1% (11/18) at 12–16 weeks’ gestation
[40] and 66.7% (12/18) at 11–14 weeks’ gestation
[37]. The chromosomal abnormalities in 11 cases of
fetal omphalocele reported by Blazer et al [40] were
trisomy 18 (n = 5), trisomy 21 (n = 2), triploidy (n = 2),
trisomy 13 (n = 1) and 45,X (n = 1), while the reported
chromosomal abnormalities in 12 cases of fetal om-
phalocele reported by Snijders et al [37] were trisomy
18 (n = 10), trisomy 13 (n = 1) and triploidy (n = 1).
Nicolaides et al [34] found that 36.2% (42/116) of
second- and third-trimester fetuses with omphalocele
had chromosomal abnormalities, including trisomy 18
(n = 32), trisomy 13 (n = 6) and other rearrangements
(n = 4). In a meta-analysis of chromosomal abnor-
malities associated with omphalocele, Chen [41] found
that 36.1% (415/1,148) of fetuses with prenatally
detected omphalocele had chromosomal abnorma-
lities, including trisomy 18 in 66.7% (277/415), tri-
somy 13 in 17.3% (72/415) and trisomy 21 in 6.3%
(26/415) of fetal omphaloceles with aneuploidy. In a
meta-analysis of 475 fetuses with prenatally detected
omphalocele, Snijders et al [3] reported chromosomal
abnormalities in 35% of fetuses, including trisomy 18
(n = 108), trisomy 13 (n = 28) and other rearrange-
ments (n = 31). Snijders et al [3] found that omphalo-
cele was diagnosed in 31% of fetuses with trisomy 18
(n = 137), 17% of fetuses with trisomy 13 (n = 54), and
2% of fetuses with triploidy (n = 50).
Papageorghiou et al [42] found omphalocele in
28.2% (51/181) of trisomy 13 fetuses in the first tri-
mester. The reported frequencies of omphalocele in the
fetuses with trisomy 13 in the second and third tri-
mesters range from 3.6% (1/28) [10] to 11.1% (2/18)
[20], 13.3% (2/15) [9], 15.2% (5/33) [7], 22.6% (7/
31) [5] and 29.4% (5/17) [6]. The mean frequency of
omphalocele in trisomy 13, based on the six published
series on second- and third-trimester fetal trisomy 13,
is 15.5% (22/142).
Diaphragmatic Hernia
The prevalence of congenital diaphragmatic hernia
(CDH) is about 1 per 4,000 births [43]. Chromosomal
abnormalities are detected in about 10% of cases with 
CDH [44–47]. Trisomies 13, 18 and 21, and 45,X are
the most common aneuploidies associated with CDH
[48–50]. Frequently reported structural chromosomal
abnormalities associated with CDH include tetrasomy
12p (Pallister-Killian syndrome), del(15) (q26.1–q26.2),
del(8)(p23.1), cytogenetic rearrangements of 8q23,
del(4)(p16), + der(22)t(11;22)(q23;q11) and del(1)
(q41–q42.12) [46,47,49,50]. Other reported chromo-
somal rearrangements associated with CDH include
duplication of 1q25–q31.2, deletion or duplication 
of 2q37, deletion of 3q22, deletion or duplication of
4q31, deletion of 5p15, deletion of 6p25, deletion 
of 6q25.3–qter, duplication of 8p21–p23.1, deletion
of 8q22–q23, deletion of 9p24–pter, deletion of
11p13, duplication of 11q23.3–qter, duplication of
12p, and duplication of 14q32 [50]. CDH has been
seen in patients with tetrasomy 21, trisomy 22, and tri-
somy 9 [49,51,52]. Autosomal deletions have been
more commonly associated with CDH than autosomal
duplications [53]. Lurie [53] has suggested that the
segments 15q26, 8p23, 8q22, 4p16, 1q42 and 3q22
are candidates for the location of genes which, when
deleted or truncated, may cause CDH, while the seg-
ments 22q11, 4q28.3q32, 1q25q31.2 and 2p23p25
are good candidates for the location of genes respon-
sible for CDH in trisomic conditions. Candidate path-
ways and genes associated with CDH include the
retinoid signaling pathway and the genes of COUP-TFII
(OMIM 107773, 15q26), FOG2 (OMIM 603693,
8q23), GATA4 (OMIM 600576, 8p23.1), WT1 (OMIM
607102, 11p13), and SLIT3 (OMIM 603745, 5q35.1)
[50]. Syndromic forms of CDH include Cornelia de Lange
syndrome, craniofrontonasal syndrome, Donnai-Barrow
syndrome, Fryns syndrome, Matthew-Wood syndrome,
multiple vertebral segmentation defects (spondylocostal
dysostosis and Jarcho-Levin syndrome), Simpson-
Golabi-Behmel syndrome, and WT1-opathies (Denys-
Drash syndrome, Frasier syndrome, and Meacham
syndrome) [46,47,50].
The frequency of CDH in trisomy 13 has been re-
ported to be 6–13% [3,5,9]. Snijders et al [3] found
that CDH was diagnosed in 10% of fetuses with trisomy
18 (n = 137), 6% of fetuses with trisomy 13 (n = 54),
and 2% of fetuses with triploidy (n = 50). Nicolaides 
et al [5] found CDH in 6.5% (2/31) of fetuses with tri-
somy 13, and Tongsong et al [9] found CDH in 13.3%
(2/15) of fetuses with trisomy 13.
The frequency of trisomy 13 in prenatally detected
CDH has been reported as 8–30%. In a meta-analysis
of 173 fetuses with prenatally diagnosed CDH, Snijders
et al [3] found chromosomal abnormalities in 18% of
fetuses, including trisomy 18 (n = 18) and other rear-
rangements (n = 14). Thorpe-Beeston et al [54] re-
ported chromosomal abnormalities in 30.6% (11/36)
of fetuses with prenatally diagnosed CDH, including
trisomy 18 (n = 6), trisomy 13 (n = 3), triploidy (n = 1)
and del(8) (n = 1). Bollmann et al [44] reported chro-
mosomal abnormalities in 13.6% (6/44) of fetuses
(n = 33) and neonates (n = 11) with CDH, including 
trisomy 18 (n = 4), partial trisomy of chromosome 
5 (n = 1) and 45,X (n = 1). Howe et al [55] reported
chromosomal abnormalities in 31.6% (12/38) of fetuses
prenatally diagnosed with CDH, including trisomy 18
(n = 2), del(4)(p16) (n = 2), mosaic trisomy 14 (n = 1),
+ dic(15) (q11.2) (n = 1), + mar(16) (n = 1), t(6;8)
(q24;q23) (n = 1), del(12) (n = 1), t(1;21)(p32;q22)
(n = 1), der(15)t(15;17)(q24.3;q23.3) (n = 1) and
del(8)(p23.1) (n = 1). Dillon et al [56] reported chro-
mosomal abnormalities in 8.5% (17/201) of fetuses
prenatally diagnosed with CDH, including trisomy 18
(n = 5), trisomy 13 (n = 3), trisomy 22 (n = 1), del(3)
(q14) (n = 2), del(3)(q11) (n = 1), del(3)(q22) (n = 1),
t(13q;14q) (n = 1), Turner syndrome (n = 1) and r(9)
(n = 1). Tonks et al [45] reported chromosomal abnor-
malities in 28.1% (27/96) of fetuses prenatally diag-
nosed with CDH, including trisomy 18 (n = 9), trisomy
13 (n = 6), + der(22)t(11;22)(q23;q11) (n = 2), del(2)
(q33q35 or q35q37) (n = 1), del(15)(q26.1) (n = 1),
tetrasomy 12p (n=1), marker chromosome (n=1), bal-
anced inversion or translocation (n = 2), additional ma-
terial of unknown origin (n=2), der(2)t(2;8)(q37;q11.2)
(n = 1) and der(7)t(2;7)(q37;q36) (n = 1). Stoll et al
[57] reported chromosomal abnormalities in 30%
(21/70) of babies with CDH and associated anom-
alies, including trisomy 18 (n = 10), trisomy 13 (n = 2),
trisomy 21 (n=1), tetrasomy 12p (n=2) and autosomal
partial deletions and/or duplications (n = 6).
Urinary Tract Abnormalities
Fetal urinary tract abnormalities occur in approximately
2–3 per 1,000 pregnancies [3]. The frequently observed
urinary tract abnormalities associated with fetal trisomy
13 include multicystic kidneys, enlarged and echogenic
kidneys, renal cystic dysplasia, hydronephrosis, and ure-
teral obstruction and duplication [7]. Nicolaides et al
[58] found that among 682 fetuses with renal defects
including mild hydronephrosis (n = 276), moderate/
severe hydronephrosis (n = 206), multicystic dysplasia
(n = 173) and renal agenesis (n = 27), chromosomal
abnormalities occurred in 85 fetuses (12.5%), includ-
ing trisomy 18 (n = 20), trisomy 21 (n = 19), trisomy 13
(n = 18), 45,X (n = 6), triploidy (n = 5), deletions (n = 9),
47,XYY (n=2) and other rearrangements. In their study,
trisomy 21 was the most common chromosomal ab-
normality (41%) associated with mild hydronephrosis,
whereas trisomy 18 and trisomy 13 were the most com-
mon chromosomal abnormalities (48%) associated with
moderate/severe hydronephrosis, multicystic dysplasia
and renal agenesis. Snijders et al [3] found that mild
hydronephrosis was diagnosed in 30% of fetuses with
trisomy 21 (n = 155), 16% of fetuses with trisomy 18
(n=137), 37% of fetuses with trisomy 13 (n=54), 4% of
fetuses with triploidy (n = 50), and 8% of fetuses with
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Turner syndrome (n = 65). They also found that the
prevalences of other renal abnormalities in trisomy 21,
trisomy 18, trisomy 13, triploidy and Turner syndrome
were 7%, 12%, 24%, 6% and 6%, respectively.
The reported frequencies of urinary tract abnormal-
ities in fetuses with trisomy 13 range from 16.7% (9/54)
[21] to 20.7% (12/58) [8], 26.7% (4/15) [9], 33.3%
(11/33) [7], 42.9% (12/28) [10], 47.1% (8/17) [6]
and 64.5% (20/31) [5]. The mean frequency of prena-
tally detected urinary tract abnormalities, based on the
seven published series on second- and third-trimester
fetal trisomy 13, is 32.2% (76/236).
Abnormal Extremities and Polydactyly
Syndactyly of the third and fourth digits is associated
with triploidy; clinodactyly with hypoplasia of the mid-
dle phalanx of the fifth digit is associated with trisomy
21; arthrogryposis, overlapping fingers, rocker-bottom
feet and talipes are associated with trisomy 18; and
polydactyly is associated with trisomy 13 [59]. Snijders
et al [3] found that abnormalities of the hands and
feet were diagnosed in 76% of fetuses with triploidy
(n = 50), 72% of fetuses with trisomy 18 (n = 137), 52%
of fetuses with trisomy 13 (n = 54), 25% of fetuses with
trisomy 21 (n = 155), and 2% of fetuses with Turner
syndrome (n = 65). The reported frequencies of abnor-
mal extremities in fetuses with trisomy 13 range from
13.8% (8/58) [8] to 33.3% (11/33) [7], 40.0% (6/15)
[9] and 67.7% (21/31) [5].
Trisomy 13 is the most common abnormality asso-
ciated with polydactyly. In a study of 338 syndromic
polydactyly cases, Castilla et al [60] found trisomy 13
in 167 cases (49.4%), Meckel syndrome in 57 cases
(16.9%), trisomy 21 in 31 cases (9.2%), hydrolethalus
syndrome in 11 cases (3.3%), VATERL association in
nine cases (2.7%), trisomy 18 in seven cases (2.1%), 
Ellis-van Creveld syndrome in seven cases (2.1%), and
miscellaneous syndromes with less than four cases in
each syndromic category. The reported frequencies of
polydactyly in fetuses with trisomy 13 range from 7.1%
(2/28) [10] to 11.1% (6/54) [21] and 21.2% (7/33) [7].
A detailed review on the frequencies of prenatal
ultrasound features reported in six studies [5,7–10,21]
of fetuses with trisomy 13 can be found in the Table in
Chen [61].
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